U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C20H17FNO4.Ca
Molecular Weight 748.781
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VIDOFLUDIMUS CALCIUM ANHYDROUS

SMILES

[Ca++].COC1=CC(=CC=C1)C2=CC=C(NC(=O)C3=C(CCC3)C([O-])=O)C(F)=C2.COC4=CC(=CC=C4)C5=CC=C(NC(=O)C6=C(CCC6)C([O-])=O)C(F)=C5

InChI

InChIKey=KWSJBFAXOPFZSO-UHFFFAOYSA-L
InChI=1S/2C20H18FNO4.Ca/c2*1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25;/h2*2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula C20H17FNO4
Molecular Weight 354.3517
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.4sc.de/wp-content/uploads/Poster-Tokyo.pdf

Vidofludimus (SC12267; 4SC-101) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. This drug is in the clinical trial for the treatment of inflammatory bowel diseases and Rheumatoid arthritis.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 134.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Phase II
1147
Unknown

Approved Use

Unknown
Palliative
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.543 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
28.4 mg 1 times / day multiple, oral
dose: 28.4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.911 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
37.8 mg 1 times / day multiple, oral
dose: 37.8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.783 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
47.3 mg 1 times / day multiple, oral
dose: 47.3 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
100.294 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
28.4 mg 1 times / day multiple, oral
dose: 28.4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
158.686 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
37.8 mg 1 times / day multiple, oral
dose: 37.8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
166.401 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
47.3 mg 1 times / day multiple, oral
dose: 47.3 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30.414 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
28.4 mg 1 times / day multiple, oral
dose: 28.4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
28.566 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
37.8 mg 1 times / day multiple, oral
dose: 37.8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
29.805 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
47.3 mg 1 times / day multiple, oral
dose: 47.3 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
substrate
1193

inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
UGT1A1
246

BCRP
910

URAT1
5

P-gp
1741
CYP2C8
810
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
2546
 inconclusive [IC50 26.837 uM]
CYP3A4
2633
 inconclusive [IC50 26.837 uM]
P-gp
1932
 inconclusive [IC50 8.1995 uM]
UGT1A1
303
 weak
BCRP
985
 yes [IC50 0.02 uM]
CYP2C9
2497
 yes [IC50 21.3174 uM]
URAT1
5
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C8
810
 major
CYP2C9
1193
 minor
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00FCHW
https://www.1pchem.com/search?query=1P00FCHW
Ambeed
A377932
http://www.ambeed.com/search/Search.html?keyword=A377932
AOBIOUS INC
AOB87354
http://aobious.com/aobious/search?search_query=AOB87354
ApexBio Technology
B4669
https://www.apexbt.com/catalogsearch/result/?q=B4669
AstaTech
40649
http://astatechinc.com/CPSResult.php?CRNO=40649
Axon MedChem
2377
https://www.axonmedchem.com/product/2377
BLD Pharm
BD630834
http://www.bldpharm.com/search/Search.html?keyword=BD630834
Cayman Chemical
18377
http://www.caymanchem.com/app/template/Product.vm/catalog/18377
Chem Scene
CS-3221
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3221
ChemShuttle
151967
https://www.chemshuttle.com/catalogsearch/result/?q=151967
Debye Scientific
DA-41592
https://www.debyesci.com/index.php?id=product&ext[cno]=DA-41592
eMolecules
50282989
https://orderbb.emolecules.com/search/#?query=50282989
eNovation Chemicals
D501823
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D501823&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A546
http://www.excenen.com/searchresultlist.php?id=EX-A546
KeyOrganics
AS-56375
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56375
Lab Network
LN01341996
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341996
mcule
MCULE-1963512370
https://mcule.com/MCULE-1963512370/
MedChem Express
HY-14908
https://www.medchemexpress.com/search.html?q=HY-14908&ft=&fa=&fp=
Molnova
M17579
https://www.molnova.com/en/serch-list.html?keywords=M17579
MolPort
MolPort-039-193-851
https://www.molport.com/shop/molecule-link/MolPort-039-193-851
MuseChem
I004676
https://www.musechem.com/product/I004676.html
Selleck Chemicals
S7262
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7262
ShangHai Biochempartner
BCP001567
http://www.biochempartner.com/search_BCP001567
ShangHai Biochempartner
BCP14555
http://www.biochempartner.com/search_BCP14555
TargetMol
T2601
https://www.targetmol.com/search?keyword=T2601
PubMed

PubMed

TitleDatePubMed
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
2010-10
New preclinical findings with vidofludimus.
2010-07
Patents

Patents

20030203951
4
20060199856
4
20070027193
4

Sample Use Guides

In Vivo Use Guide
at a dose of 35 mg once daily
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Peripheral blood mononuclear cells (PBMCs) from healthy human donors were used to evaluate cellular proliferation and cytokine (IL-17, TNF-α) production. 4SC-101 (VIDOFLUDIMUS) is a potent inhibitor of human Dihydroorotate dehydrogenase (DHODH), inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes.
Unknown
Substance Class Chemical
Created
by admin
on Tue Apr 01 22:48:28 GMT 2025
Edited
by admin
on Tue Apr 01 22:48:28 GMT 2025
Record UNII
FW5VY7926X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VIDOFLUDIMUS CALCIUM ANHYDROUS
Common Name English
Vidofludimus calcium [WHO-DD]
Preferred Name English
1-CYCLOPENTENE-1-CARBOXYLIC ACID, 2-(((3-FLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)CARBONYL)-, CALCIUM SALT (2:1)
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C172652
Created by admin on Tue Apr 01 22:48:28 GMT 2025 , Edited by admin on Tue Apr 01 22:48:28 GMT 2025
PRIMARY
CAS
1354012-90-0
Created by admin on Tue Apr 01 22:48:28 GMT 2025 , Edited by admin on Tue Apr 01 22:48:28 GMT 2025
PRIMARY
FDA UNII
FW5VY7926X
Created by admin on Tue Apr 01 22:48:28 GMT 2025 , Edited by admin on Tue Apr 01 22:48:28 GMT 2025
PRIMARY
PUBCHEM
56944639
Created by admin on Tue Apr 01 22:48:28 GMT 2025 , Edited by admin on Tue Apr 01 22:48:28 GMT 2025
PRIMARY
SMS_ID
100000184307
Created by admin on Tue Apr 01 22:48:28 GMT 2025 , Edited by admin on Tue Apr 01 22:48:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of VIDOFLUDIMUS CALCIUM MONOHYDRATE
SOLVATE->ANHYDROUS
Structure of VIDOFLUDIMUS CALCIUM DIHYDRATE
SOLVATE->ANHYDROUS
Structure of VIDOFLUDIMUS
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of VIDOFLUDIMUS
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966